The Future of Biomedical Research and Innovation | Future of Health Summit 2025

Current State of the U.S. Biomedical Ecosystem

• The U.S. biomedical research system, established in 1945 by Vannevar Bush's "Science, the Endless Frontier," relies on six to seven pillars: federal funding, universities, industry (biopharma), immigration/manpower, philanthropy, venture capital, and regulatory oversight (FDA).
• A "perfect storm" is currently attacking every pillar of this ecosystem for distinct reasons:
  • Federal Funding: The Office of Management and Budget (OMB) seeks a 40% reduction in NIH funding to correct the deficit, though Congress has so far refused to lower the budget.
  • Universities: There is an ideological push to shift institutions from the "far left" to the center, resulting in a 30% reduction in graduate students at some schools.
  • Industry: Biopharma is under pressure regarding high drug pricing and public perception of gouging.
  • Immigration: Policies are reducing the influx of international talent, despite the U.S. comprising only 4% of the global population while holding 25% of the global economy.
• While the U.S. has driven 50% of economic growth over the last century through medical research and significantly increased life expectancy, the current trajectory threatens to dismantle 75 years of progress.
• Competitors are actively leveraging the U.S.'s relative stagnation:
  • China: Has amassed resources to beat the U.S. in biomedical innovation through central coordination.
  • Scandinavia & Singapore: Utilize centralized national data systems and patient identifiers to optimize resource allocation and population health outcomes (e.g., Singapore expects teens to live to 100).
  • Ireland: Has surpassed the U.S. in life expectancy (84 vs. 78 years) due to better primary care and social systems.

Critical Disparities in Healthcare Delivery and Trust

• Implementation Gap: There is a profound disconnect between the U.S.'s premier research engine and its broken healthcare delivery system; the country spends $5.4 trillion (7-8% increase in 2025) but ranks lowest in primary care access and life expectancy among high-income nations.
• CMS Budget Disparity: The Centers for Medicare & Medicaid Services (CMS) spends over $1.75 trillion annually on healthcare, yet allocates less than $1 billion to research and implementation, compared to a requested $17 billion (1% of premiums).
• Trust Erosion: Public trust in science and institutions is declining due to:
  • High out-of-pocket costs and medical bankruptcy.
  • An "institutional capture" where 40% of healthcare expenditures flow to intermediaries (PBMs) rather than direct care.
  • The rise of 24/7 social media misinformation that outcompetes traditional academic press releases and journal articles.
• Social Determinants: Wealth disparity is identified as a primary driver of poor health outcomes; life expectancy in the U.S. is currently hampered by factors like uncontrolled blood pressure (averaging <50% of controlled) and the opioid crisis, rather than a lack of technology.
• Gun Violence: The leading cause of death for U.S. children is firearms, a factor unrelated to biomedical research but critical to national health metrics.

Strategic Recommendations and Future Vision

• Data Infrastructure: A move toward a federated national health infrastructure is proposed to allow "count once, use numerous times" data sharing (e.g., via the "Data Counts" initiative), enabling efficient patient identification for clinical trials while maintaining privacy.
• Workforce & Education:
  • The Alice Walton School of Medicine model targets rural populations by recruiting 15% of students from rural backgrounds (vs. <5% national average) to serve high-need areas.
  • Curriculum changes emphasize "whole health" approaches that address social, emotional, and economic needs alongside disease treatment.
• Philanthropy's Evolving Role: Private philanthropy is shifting from passive giving to proactive, impact-driven investment, potentially filling funding gaps as government investment remains stagnant; however, risks include potential taxation of endowments and the need to avoid destroying the "golden goose."
• Incentive Alignment: The report advocates for aligning financial incentives to prioritize prevention and primary care, citing Kaiser Permanente as a model where health outcomes (e.g., >90% blood pressure control) align with payer interests.
• National Life Sciences Strategy: A call for a unified, centrally coordinated national strategy to replace the current "no conductor" approach, modeled after competitive adversaries like China and Singapore.
• Call to Action:
  • Political Engagement: Leaders and scientists must engage policymakers with evidence and stories, emphasizing that losing the "prime mover advantage" in science (e.g., AI algorithms) means losing global leadership.
  • Voter Mobilization: The ultimate mechanism for change is informed voting to support policies that restore funding, protect immigration talent pipelines, and fix the healthcare delivery system.
  • Collaboration: Ecosystem players must "get rid of egos," partner across sectors (academic, industry, government, patient), and coordinate efforts to avoid the risk of a decade-long lag in innovation.